No Data
Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), TScan Therapeutics (TCRX)
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals(APLS.US) Officer Sells US$3.34 Million in Common Stock
$Apellis Pharmaceuticals(APLS.US)$ Officer Deschatelets Pascal sold 78,907 shares of common stock on May 8, 2024 at an average price of $42.3517 for a total value of $3.34 million.Source: Announcement
Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing
Pascal Deschatelets, Chief Scientific Officer, on May 08, 2024, sold 78,907 shares in Apellis Pharmaceuticals (APLS) for $3,341,848. Following the Form 4 filing with the SEC, Deschatelets has control
When Can We Expect A Profit From Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)?
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Apellis Pharmaceuticals, Inc., a commerci
Form 144 | Apellis Pharmaceuticals(APLS.US) Officer Proposes to Sell 3.34 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 8, $Apellis Pharmaceuticals(APLS.US)$ Officer Deschatelets Pascal intends to sell 78,907 shares of its common stock on May 8, with a total market value of approximately $3.